Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results
about
Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness AnalysisLong-Term PEG-J Tube Safety in Patients With Advanced Parkinson's DiseaseAn Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureProblems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients.Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safetyIntegrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion.Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region.New treatments for levodopa-induced motor complications.Carbidopa levodopa enteral suspension.New and emerging medical therapies in Parkinson's disease.A review of current and novel levodopa formulations for the treatment of Parkinson's disease.Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.Novel Levodopa Formulations for Parkinson's Disease.Algorithms for the treatment of motor problems in Parkinson's disease.The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa-carbidopa intestinal gel.Practical approaches to commencing device-assisted therapies for Parkinson's disease in Australia.Intrajejunal levodopa infusion therapy for Parkinson's disease: practical and pragmatic tips for successful maintenance of therapy.Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson's diseaseInitiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.Levodopa: A new look at an old friend.Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease.Suicide in Parkinson's Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel.Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics.Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.
P2860
Q26779605-6A85D628-2507-47BC-9292-DC3F1557EEE7Q27325443-D4FCE4EA-8A57-41DC-AFF9-539B509D1D47Q33890861-89C58035-E295-4621-86D7-809D8B937F8EQ33917283-1D5EFB4F-1E43-4990-9E30-A9EA3D1EB3EFQ33917419-302D7B2B-4E71-4435-A440-17933A475953Q33917449-E39A951A-0FE7-44EC-BF3F-2FAF187EEAFBQ36025896-F61B676E-D4CA-4ED0-B971-1F079E75AFB1Q37340428-02EE786E-8E98-4288-81A0-D1A11D02831BQ37342303-E5F31468-240F-462F-ADAB-0FA479338F3DQ37344109-7821A20B-116F-4B71-98AA-760D74FA5079Q37698585-C35DEB3B-64F5-4653-B872-B3F316BF27B0Q38371848-81AAACB0-174E-4F0D-B660-70D8292BC05BQ38530328-2DC60A1C-3B01-42AF-9480-ED26257DD969Q38570434-374FC4A4-47F3-4880-A497-05469610529DQ38643494-19E6126F-FBBA-4532-987E-A13D863AC5ABQ38718194-10E70103-16B0-492C-B286-55C7F619DF22Q38740274-85702833-8888-43EF-A9A7-56FA29853F7EQ38823793-72527718-B95D-4041-934D-0D17253C6FD0Q38981419-FCEECD7C-C138-49FA-BC85-69CB1386E5C1Q38992788-EE3FA357-7FF3-49EE-AEA1-F3412D3851FCQ39099746-7ECD682C-82B4-4AF0-850A-FAAA4B191202Q39134831-B4755720-7CB6-4B8F-8A8A-EBE58CF8F58FQ39240060-A973C79F-AFD7-4678-BA11-8EE65FDC39F6Q39578837-32C2D0F2-5251-435D-9202-D1855783684EQ40551791-411B6067-5883-48A9-A342-C4C67F5DAE45Q40694060-8C6DA16C-2BC0-4697-BEE2-3B7B62EA10E2Q41055649-B838D5E8-2341-4A53-BE1C-D3C1F05A04B1Q46617404-02199FA7-4837-4E55-A016-D1ACAB889BC8Q47120831-DFD06C28-5DBC-4CE1-8B9E-138D5AB539A3Q47274330-552FB159-C60D-41FE-93C1-365558AF0B79Q47652358-B72E33B2-2FB0-41DC-AE8C-8391CFFDE280Q47880422-BEAD0F02-BE56-45D4-8E93-4882CEAA60B0Q47948932-9AE0AEA0-F07B-4469-90F1-FF2185A5D871Q47962428-0FBF5309-91C2-4DB6-95D5-50938689E8DAQ47997995-41035A85-6813-41B8-AE79-B819344F2B86Q48072883-E4A23F6E-719D-4576-B048-946E3409064FQ48078173-B2BC6AB2-75DE-4489-9BE2-54A844A84C9BQ48128791-7C47BD0D-0B36-489F-8BED-33FAFB2A5E4DQ53143036-2C3A609F-F253-43D5-9C9B-B019FAC189B1Q53661046-276F349C-F91B-47E4-9CDF-B5FF34565979
P2860
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Levodopa-carbidopa intestinal ...... l 12-month, open-label results
@ast
Levodopa-carbidopa intestinal ...... l 12-month, open-label results
@en
type
label
Levodopa-carbidopa intestinal ...... l 12-month, open-label results
@ast
Levodopa-carbidopa intestinal ...... l 12-month, open-label results
@en
prefLabel
Levodopa-carbidopa intestinal ...... l 12-month, open-label results
@ast
Levodopa-carbidopa intestinal ...... l 12-month, open-label results
@en
P2093
P2860
P50
P356
P1433
P1476
Levodopa-carbidopa intestinal ...... l 12-month, open-label results
@en
P2093
Alberto J Espay
Coleen M Hall
David G Standaert
Eduard Z Yakupov
Fabian Klostermann
Janet A Benesh
Jordan Dubow
Krai Chatamra
Malcolm Steiger
Mark F Lew
P2860
P304
P356
10.1002/MDS.26123
P407
P577
2014-12-24T00:00:00Z